Lyra Health vs Becton Dickinson

Side-by-side comparison of AI visibility scores, market position, and capabilities

Becton Dickinson leads in AI visibility (79 vs 58)
Lyra Health logo

Lyra Health

ChallengerHealthcare Tech

Mental Health Benefits & Digital Therapeutics

Leading mental health benefits platform for employers. Founded 2015 by ex-Facebook CFO. $5.58B valuation, $915M total funding. Serves 20M+ people through employer contracts.

AI VisibilityBeta
Overall Score
C58
Category Rank
#143 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
52
Perplexity
53
Gemini
56

About

Lyra Health is a workforce mental health platform founded in 2015 by David Ebersman (former CFO of Facebook/Meta) and Dena Bravata, headquartered in Burlingame, California. It provides AI-powered mental health benefits to employers through therapy, coaching, preventive care, specialized programs (substance use, DBT), and the Empower AI platform for personalized support.

Full profile
Becton Dickinson logo

Becton Dickinson

LeaderHealthcare Tech

Enterprise

Franklin Lakes NJ medical technology (NYSE: BDX) at $21.8B FY2025 revenue (+8.2%); $17.5B Reverse Morris Trust spinoff with Waters (2025), Edwards critical care acquisition $4.2B (2024) competing with Baxter for infusion systems.

AI VisibilityBeta
Overall Score
B79
Category Rank
#25 of 596
AI Consensus
77%
Trend
stable
Per Platform
ChatGPT
76
Perplexity
82
Gemini
84

About

Becton, Dickinson and Company (BD) is a Franklin Lakes, New Jersey-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BDX) as an S&P 500 Health Care component — manufacturing and selling medical supplies, devices, laboratory equipment, and diagnostic products through approximately 74,000 employees serving healthcare institutions, clinical laboratories, pharmaceutical companies, and life science researchers in over 190 countries. In fiscal year 2025 (ended September 30, 2025), BD reported full-year revenue of $21.8 billion (up 8.2% year-over-year) with Q4 FY2025 revenue of $5.9 billion (+8.3% reported, +3.9% organic growth), and declared a quarterly dividend of $1.05 per share (+1%). Founded in 1897 in New York City by Maxwell Becton and Fairleigh Dickinson Sr. as a thermometer and surgical instrument maker, BD has grown through 125+ years of acquisitions to become a Fortune 500 ($21.8B revenue, #211 on 2024 Fortune 500) global medtech leader. The company operates through three segments: BD Medical (~50% of revenue, IV catheters, syringes, prefillable drug delivery systems, and medication management solutions), BD Life Sciences (flow cytometry, microbiology, molecular diagnostics, and lab automation), and BD Interventional (advanced patient monitoring, interventional cardiology, and peripheral vascular interventions). BD invests $1.2+ billion annually in R&D. In 2024, BD acquired Edwards Lifesciences' critical care monitoring unit for $4.2 billion.

Full profile

AI Visibility Head-to-Head

58
Overall Score
79
#143
Category Rank
#25
71
AI Consensus
77
stable
Trend
stable
52
ChatGPT
76
53
Perplexity
82
56
Gemini
84
57
Claude
84
64
Grok
77

Key Details

Category
Mental Health Benefits & Digital Therapeutics
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Lyra Health
Mental Health Benefits & Digital Therapeutics

Integrations

Only Lyra Health
Only Becton Dickinson
Becton Dickinson is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.